{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T14:07:45Z","timestamp":1778335665332,"version":"3.51.4"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001691","name":"JSPS","doi-asserted-by":"publisher","award":["20K08396"],"award-info":[{"award-number":["20K08396"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cancer and cardiovascular disease share several risk factors. Clonal heamatopoiesis, a novel risk factor associated with both diseases, has received increasing attention in the fields of cardiology, heamatology and oncology. Clonal heamatopoiesis of indeterminate potential refers to the presence of at least one driver mutation in the heamatopoietic cells of peripheral blood without heamatological malignancy. Clonal heamatopoiesis of indeterminate potential is a common age-related condition that affects up to 60% of individuals aged\u00a0&amp;gt;\u00a080 years. Importantly, clonal heamatopoiesis of indeterminate potential carriers have a 2- to 4-fold higher risk of developing cardiovascular disease than non-carriers. Therefore, we performed an up-to-date review of clonal heamatopoiesis and its association with various forms of cardiovascular disease, including atherosclerotic disease, heart failure, aortic stenosis and pulmonary hypertension. In addition, we reviewed experimental studies that examined the causality and directionality between clonal heamatopoiesis and cardiovascular disease. Lastly, we discussed future research directions that will aid in the design of personalized therapies and preventive strategies for individuals with clonal heamatopoiesis. This review showed that clonal heamatopoiesis of indeterminate potential is a common condition, especially in older patients, and is associated with an increased risk of cardiovascular disease and worse prognosis. However, further research is needed to determine whether anti-inflammatory therapies or therapies that can reduce or eliminate clone size are effective in preventing cardiovascular disease in patients with clonal heamatopoiesis of indeterminate potential.<\/jats:p>","DOI":"10.1093\/jjco\/hyac210","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T16:52:22Z","timestamp":1673455942000},"page":"187-194","source":"Crossref","is-referenced-by-count":4,"title":["Clonal heamatopoiesis and associated cardiovascular diseases"],"prefix":"10.1093","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-1008","authenticated-orcid":false,"given":"Kazuko","family":"Tajiri","sequence":"first","affiliation":[{"name":"National Cancer Center Hospital East Department of Cardiology, , Kashiwa, Japan"},{"name":"University of Tsukuba Department of Cardiology, Faculty of Medicine, , Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Suehara","sequence":"additional","affiliation":[{"name":"University of Tsukuba Hospital Department of Hematology, , Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Suzuki","sequence":"additional","affiliation":[{"name":"University of Tsukuba Department of Medical Oncology, Faculty of Medicine, , Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1105-7339","authenticated-orcid":false,"given":"Ikuo","family":"Sekine","sequence":"additional","affiliation":[{"name":"University of Tsukuba Department of Medical Oncology, Faculty of Medicine, , Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"key":"2023030723341899600_","author":"WHO | World Health Organization"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/jjco\/hyx068","article-title":"Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients","volume":"47","author":"Tajiri","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/CIRCRESAHA.121.319809","article-title":"Somatic mutations in cardiovascular disease","volume":"130","author":"Heimlich","year":"2022","journal-title":"Circ Res"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s11886-022-01724-2","article-title":"Somatic mutations and clonal hematopoiesis as drivers of age-related cardiovascular risk","volume":"24","author":"Haring","year":"2022","journal-title":"Curr Cardiol Rep"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan4673","article-title":"Clonal hematopoiesis in human aging and disease","volume":"366","author":"Jaiswal","year":"2019","journal-title":"Science"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1001\/jamacardio.2019.0302","article-title":"Connections between clonal hematopoiesis, cardiovascular disease, and cancer: a review","volume":"4","author":"Calvillo-Arg\u00fcelles","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1182\/bloodadvances.2020004062","article-title":"Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged \u226580 years","volume":"5","author":"Zeventer","year":"2021","journal-title":"Blood Adv"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood.2021011320","article-title":"Clinical relevance of clonal hematopoiesis in persons aged \u226580 years","volume":"138","author":"Rossi","year":"2021","journal-title":"Blood"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12484","article-title":"Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults","volume":"7","author":"Young","year":"2016","journal-title":"Nat Commun"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.stem.2022.05.006","article-title":"Clonal hematopoiesis: mutation-specific adaptation to environmental change","volume":"29","author":"Florez","year":"2022","journal-title":"Cell Stem Cell"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.molmed.2022.03.002","article-title":"Advances in understanding the molecular basis of clonal hematopoiesis","volume":"28","author":"Alagpulinsa","year":"2022","journal-title":"Trends Mol Med"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1182\/blood-2015-08-667063","article-title":"MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance","volume":"126","author":"Kwok","year":"2015","journal-title":"Blood"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N Engl J Med"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/blood-2011-12-399337","article-title":"Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes","volume":"119","author":"Thol","year":"2012","journal-title":"Blood"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.3324\/haematol.2014.104406","article-title":"ETV6 mutation in a cohort of 970 patients with hematologic malignancies","volume":"99","author":"Wang","year":"2014","journal-title":"Haematologica"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.yjmcc.2021.07.004","article-title":"Clonal hematopoiesis of indeterminate potential (CHIP): linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease","volume":"161","author":"Marnell","year":"2021","journal-title":"J Mol Cell Cardiol"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","article-title":"DNMT3A mutations in acute myeloid leukemia","volume":"363","author":"Ley","year":"2010","journal-title":"N Engl J Med"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nature12750","article-title":"TET enzymes, TDG and the dynamics of DNA demethylation","volume":"502","author":"Kohli","year":"2013","journal-title":"Nature"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1161\/CIRCRESAHA.118.313225","article-title":"CRISPR-mediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease","volume":"123","author":"Sano","year":"2018","journal-title":"Circ Res"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jacc.2017.12.037","article-title":"Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1\u03b2\/NLRP3 inflammasome","volume":"71","author":"Sano","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.immuni.2022.06.022","article-title":"DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages","volume":"55","author":"Cobo","year":"2022","journal-title":"Immunity"},{"key":"2023030723341899600_","first-page":"1579","article-title":"Dirty jobs: macrophages at the heart of cardiovascular disease","volume":"10","author":"Stevens","year":"2022","journal-title":"Biomedicine"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nri.2017.21","article-title":"Mitochondrial DNA in innate immune responses and inflammatory pathology","volume":"17","author":"West","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.exphem.2020.01.002","article-title":"ASXL1 mutation in clonal hematopoiesis","volume":"83","author":"Fujino","year":"2020","journal-title":"Exp Hematol"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41586-020-2819-2","article-title":"Inherited causes of clonal haematopoiesis in 97,691 whole genomes","volume":"586","author":"Bick","year":"2020","journal-title":"Nature"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1038\/s41375-020-0896-8","article-title":"Clonal myelopoiesis in the UK biobank cohort: ASXL1 mutations are strongly associated with smoking","volume":"34","author":"Dawoud","year":"2020","journal-title":"Leukemia"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3389\/fcell.2022.942053","article-title":"JAK2 alterations in acute lymphoblastic leukemia: molecular insights for superior precision medicine strategies","volume":"10","author":"Downes","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jjcc.2022.02.001","article-title":"Clonal hematopoiesis and cardiovascular diseases: role of JAK2V617F","volume":"81","author":"Misaka","year":"2022","journal-title":"J Cardiol"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"E35","DOI":"10.1161\/CIRCRESAHA.118.313283","article-title":"Macrophage inflammation, erythrophagocytosis, and accelerated atherosclerosis in Jak2 V617F mice","volume":"123","author":"Wang","year":"2018","journal-title":"Circ Res"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41586-021-03341-5","article-title":"The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis","volume":"592","author":"Fidler","year":"2021","journal-title":"Nature"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","DOI":"10.1172\/JCI155724","article-title":"Erythroid lineage Jak2V617F expression promotes atherosclerosis through erythrophagocytosis and macrophage ferroptosis","volume":"132","author":"Liu","year":"2022","journal-title":"J Clin Invest"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1161\/CIRCRESAHA.114.302721","article-title":"Mechanisms of plaque formation and rupture","volume":"114","author":"Bentzon","year":"2014","journal-title":"Circ Res"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jacbts.2019.05.013","article-title":"JAK2 V617F -mediated clonal hematopoiesis accelerates pathological remodeling in murine heart failure","volume":"4","author":"Sano","year":"2019","journal-title":"JACC Basic to Transl Sci"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.3324\/haematol.2020.264085","article-title":"Crucial role of hematopoietic JAK2 V617F in the development of aortic aneurysms","volume":"106","author":"Yokokawa","year":"2021","journal-title":"Haematologica"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41467-021-26435-0","article-title":"Clonal hematopoiesis with JAK2V617F promotes pulmonary hypertension with ALK1 upregulation in lung neutrophils","volume":"12","author":"Kimishima","year":"2021","journal-title":"Nat Commun"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.119.044362","article-title":"Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal Hematopoiesis","volume":"141","author":"Bick","year":"2020","journal-title":"Circulation"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jamacardio.2018.3965","article-title":"Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure","volume":"4","author":"Dorsheimer","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/eurheartj\/ehaa845","article-title":"Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations","volume":"42","author":"Assmus","year":"2021","journal-title":"Eur Heart J"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/CIRCRESAHA.120.317104","article-title":"Clonal hematopoiesis-driver DNMT3A mutations alter immune cells in heart failure","volume":"128","author":"Abplanalp","year":"2021","journal-title":"Circ Res"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.jacc.2021.02.028","article-title":"Clonal hematopoiesis and risk of progression of heart failure with reduced left ventricular ejection fraction","volume":"77","author":"Pascual-Figal","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jacc.2021.04.085","article-title":"Supplemental association of clonal hematopoiesis with incident heart failure","volume":"78","author":"Yu","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1126\/science.aay9333","article-title":"The evolutionary dynamics and fitness landscape of clonal hematopoiesis","volume":"367","author":"Watson","year":"2020","journal-title":"Science"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/eurheartj\/ehz591","article-title":"Clonal haematopoiesis in patients with degenerative aortic valve stenosis undergoing transcatheter aortic valve implantation","volume":"41","author":"Mas-Peiro","year":"2020","journal-title":"Eur Heart J"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jamacardio.2020.2468","article-title":"Association of clonal hematopoiesis of indeterminate potential with inflammatory gene expression in patients with severe degenerative aortic valve stenosis or chronic postischemic heart failure","volume":"5","author":"Zeiher","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1253\/circj.CJ-19-0133","article-title":"JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome","volume":"83","author":"Kimura","year":"2019","journal-title":"Circ J"},{"key":"2023030723341899600_","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/jamacardio.2022.0386","article-title":"TET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial","volume":"7","author":"Svensson","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2023030723341899600_","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/3\/187\/49444633\/hyac210.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/3\/187\/49444633\/hyac210.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T10:09:21Z","timestamp":1679220561000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/53\/3\/187\/6982736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":58,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,1,10]]},"published-print":{"date-parts":[[2023,3,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyac210","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3]]},"published":{"date-parts":[[2023,1,10]]}}}